EISAI CO LTD

New Eisai‑Pfizer partnership will launch Nurtec® for acute & preventive migraine in Japan, backed by robust Phase‑3 efficacy, safety, and real‑world benefit data.

Real‑world evidence shows LEQEMBI stabilizes early Alzheimer’s disease, with 80 % of patients maintaining disease stage and a favorable safety profile.

Subcutaneous lecanemab offers the same exposure, efficacy and safety as IV, enabling weekly home injections for early Alzheimer’s patients.

Discover EISAI’s breakthrough glioma therapy—FDA‑designated, biomarker‑driven, and showing early disease stabilization with a favorable safety profile.

Discover how EISAI’s diversified EGFR‑targeted pipeline—spanning small molecules, bispecific antibodies, and ADCs—positions the company to lead the next wave of precision oncology therapies.

Explore Eisai’s FY 2029 outlook: Leqembi’s projected ¥300 bn revenue, robust AD data, and growth in Dayvigo and Lenvima – a balanced neuro‑oncology strategy.

Discover how Eisai’s lenvatinib strategy and upcoming ASCO data could reshape oncology pricing and market share, balancing cost‑efficiency with patient outcomes.

Discover how Eisai’s Q1 2026 results show a modest EPS decline yet strong revenue growth, driven by breakthrough trials in Alzheimer’s, obesity, and oncology.

Leqembi sales to hit ¥143.5 bn in FY 2026, driving a 35% rise in Eisai’s attributable profit and solidifying its role in global Alzheimer’s care.

Read how Eisai’s LITESPARK‑012 failure reshapes its RCC strategy and what Merck & Co. can learn for future oncology collaborations.